
==== Front
J Transl Med
J Transl Med
Journal of Translational Medicine
1479-5876
BioMed Central London

5599
10.1186/s12967-024-05599-5
Research
AAV-DJ is superior to AAV9 for targeting brain and spinal cord, and de-targeting liver across multiple delivery routes in mice
Chauhan Monika 1
Daugherty Audrey L. 1
Khadir Fatemeh (Ellie) 1
Duzenli Ozgun F. 2
Hoffman Alexandra 3
Tinklenberg Jennifer A. 1
Kang Peter B. 1
Aslanidi George 2
http://orcid.org/0000-0002-7430-124X
Pacak Christina A. cpacak@umn.edu

1
1 grid.17635.36 0000000419368657 Department of Neurology, Greg Marzolf Jr. Muscular Dystrophy Center, University of Minnesota Medical School, 420 Delaware Street SE, MMC 295, Minneapolis, Minnesota, MN 55455 USA
2 grid.17635.36 0000000419368657 The Hormel Institute, University of Minnesota, Austin, MN USA
3 https://ror.org/04rq5mt64 grid.411024.2 0000 0001 2175 4264 University of Maryland, Baltimore, MD USA
5 9 2024
5 9 2024
2024
22 82417 5 2024
12 8 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by/4.0/ Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
Highly efficient adeno associated viruses (AAVs) targeting the central nervous system (CNS) are needed to deliver safe and effective therapies for inherited neurological disorders. The goal of this study was to compare the organ-specific transduction efficiencies of two AAV capsids across three different delivery routes. We compared AAV9-CBA-fLucYFP to AAV-DJ-CBA-fLucYFP using the following delivery routes in mice: intracerebroventricular (ICV) 1 × 1012 vg/kg, intrathecal (IT) 1 × 1012 vg/kg, and intravenous (IV) 1 × 1013 vg/kg body weight. Our evaluations revealed that following ICV and IT administrations, AAV-DJ demonstrated significantly increased vector genome (vg) uptake throughout the CNS as compared to AAV9. Through the IV route, AAV9 demonstrated significantly increased vg uptake in the CNS. However, significantly fewer vgs were detected in the off-target organs (kidney and liver) following administration of AAV-DJ using the IT and IV delivery routes as compared to AAV9. Distributions of vgs correlate well with transgene transcript levels, luciferase enzyme activities, and immunofluorescence detection of YFP. Overall, between the two vectors, AAV-DJ resulted in better targeting and expression in CNS tissues paired with de-targeting and reduced expression in liver and kidneys. Our findings support further examination of AAV-DJ as a gene therapy capsid for the treatment of neurological disorders.

Supplementary Information

The online version contains supplementary material available at 10.1186/s12967-024-05599-5.

Keywords

AAV capsids
AAV9
AAV-DJ
Gene therapy
Intravenous
Intrathecal
Intracerebroventricular
Neurological
Brain
Spinal cord
http://dx.doi.org/10.13039/100022416 Center for Drug Evaluation and Research R01FD007483 issue-copyright-statement© BioMed Central Ltd., part of Springer Nature 2024
==== Body
pmcIntroduction

More than 430 gene therapy trials currently listed on clinicaltrials.gov (https://clinicaltrials.gov/search?term=%E2%80%9Cgene%20therapy&viewType=Table&cond=Central%20Nervous%20System%20Diseases&locStr=United%20States&country=United%20States accessed on July 16, 2024) are underway in the United States to investigate a wide variety of gene delivery vehicles for both gene replacement and genome editing therapeutic strategies. The gene therapy field has made significant advancements over the last few decades as there are now Food and Drug Administration (FDA) approved therapies for multiple genetically inherited disorders that were once considered untreatable [1–9].

Adeno-associated virus (AAV) is one of the most efficient vehicles available to deliver healthy gene cDNA sequences into the cells of affected individuals due to its ability to persist for long periods of time as an episome within the nuclei of cells, its relatively non-pathogenic nature, and its ability to infect dividing and non-dividing cells in vivo [10, 11]. Despite these advantages, one key challenge related to the use of AAV includes the high doses currently required to achieve a sufficient therapeutic effect. High doses of intravenously administered AAV can elicit responses in both the innate and adaptive immune systems [12–14]. There are both vector-dependent and host-dependent factors that influence the immunogenicity of AAV capsids and subsequent severity of immune responses [14, 15]. Major obstacles related to immune responses include the presence of host neutralizing antibodies against AAV [16] and the activation of CD4+ and CD8+ T cells in response to degradation of either capsid or transgene-encoded proteins by the proteasome [17]. These inflammatory responses can be further amplified by activation of the alternative complement pathway through direct interactions between complement component C3 and AAV capsid proteins [12]. Efforts to reduce the therapeutic dose to help increase safety, reduce immune responses, and improve the therapeutic efficacy of gene therapies promise to yield significant clinical benefits. One approach to improve AAV-based therapeutics is to develop synthetic capsid serotypes, such as AAV-DJ, that are optimal for transducing desired organs and cell types while simultaneously avoiding off-target organs and evading immune responses. Another approach to target desired regions is to perform AAV administrations through different delivery routes, such as intrathecal (IT) delivery to further improve CNS targeting [18, 19].

Our interest in the development of AAV-mediated gene-based therapies for rare neurological disorders led us to explore novel capsids for targeting specific regions and cells within the brain and spinal cord. Genetic disorders associated with neurological pathologies are particularly difficult to treat. This is in part due to challenges associated with the penetration of the highly protective blood-brain barrier (BBB) and central nervous system (CNS) complexities that can result in limited access to the brain’s deep structures. Unique AAV capsid motifs for each serotype are critical for binding to host cells and represent a key step in the specificity of AAV-mediated gene delivery. We thus compared the AAV9 capsid currently used in the FDA approved gene therapy for spinal muscular atrophy (SMA) (onasemnogene abeparvovec-xioi) to the AAV-DJ synthetic capsid that was developed by shuffling naturally occurring serotypes [20]. AAV-DJ was recently demonstrated to be superior for the broad transduction of neurological tissue in a non-human primate study [21] and was originally selected in part, due to the lower prevalence of neutralizing AAV-DJ antibodies in humans [20].

Another important consideration is the gene therapy delivery route. Therefore, we also compared the efficiency of AAV9 and AAV-DJ capsids across three different delivery routes with respect to their ability to target the CNS and simultaneously de-target the liver and kidney. We are particularly keen to avoid the liver as AAVs that are delivered systemically tend to be sequestered in the liver [22, 23] This leads to reduced transduction of target (non-liver) organs and potentially liver toxicity [24, 25], which may in some cases be fatal [26]. Our study will help optimize capsid selection and delivery route for CNS gene therapies.

Materials and methods

AAV production and purification

Both AAV9 and AAV-DJ vectors were packaged in a single-strain expression cassette with chicken β-actin (CBA) promoter-driven fusion of firefly luciferase (fLuc), and yellow fluorescent protein (YFP) [27, 28]. Recombinant AAV vectors were produced using the triple transfection method and purified as described previously [29, 30]. Briefly, HEK293 cells were co-transfected with three plasmids encoding (1) Rep/Cap, (2) ITRs-CBA-fLuc-YFP, and (3) Ad helper genes using polyethyleneimine (#23966-1, Polysciences, USA). Cells were harvested 72 h post transfection, subjected to freeze-thaw cycles, and treated with Benzonase (#E8263, Sigma-Aldrich, USA) at 37 °C for 1 h. The suspension was purified by Iodixanol (#D1556, Sigma-Aldrich, USA) gradient ultracentrifugation followed by ion exchange chromatography using HiTrap Q HP (Cytiva, USA) with Bis-Tris propane-MgSO4 buffer. Subsequently, the vector preparation was concentrated into 10 mM Tris – 100 mM sodium citrate buffer (pH 7) using centrifugal spin concentrators (#AP2015010, Orbital Biosciences, USA).

Quantitative PCR analysis for the determination of AAV titers

For vector genome (vg) titer determination, DNA contaminants were removed by TURBO DNase (#REF4022G, Thermo Fisher Scientific, USA) digestion. AAV genomes were then released from AAV capsids by Proteinase K (#AM2546, Invitrogen, USA) digestion. Subsequently, the viral DNA was cleaned using DNA Clean & Concentrator™ 25 (#11-305 C, Genesee Scientific, USA). Vector titers were quantified by qPCR with a TBGreen Advantage (#S4748, Takara Bio, USA), using the following primer pair specific to the CBA promoter region within the viral cassette: forward primer 5’-TCCCATAGTAACGCCAATAGG − 3’ and reverse primer 5’-CTTGGCATATGATACACTTGATG − 3’ [29, 30].

Animals

All husbandry and procedural use of animals was approved by the Institutional Animal Care and Use Committee (IACUC) at the University of Minnesota (UMN). All the FVB/NJ (stock# 001800) mice (5 weeks old) were ordered from Jackson Laboratory. The mice were maintained at 25 °C and 50% humidity in the Research Animal Resources facility at UMN. Animals were maintained in 14/10 h light/dark cycles and fed chow and water ad libitum. All animals used in the study were acclimatized in the vivarium and handled for one week prior to initiation of the study.

Routes of AAV delivery

Equal numbers of males and females were used for each delivery route and capsid. In total, for every route, 10 (5 males and 5 females) 6-week-old mice were injected with AAV9-CBA-fLuc/YFP and 10 (5 males and 5 females) 6-week-old mice were injected with AAV-DJ-CBA-fLuc/YFP.

Jugular vein injection (IV)

IV administration was performed as previously described [31, 32]. Briefly, mice were anesthetized with inhaled 1–3% isoflurane (Dechra, USA). A small incision (~ 0.5 cm) was made parallel to the midline at the lower third of the right anterior neck, exposing the right external jugular vein. A 28-gauge insulin needle was bent on the sterile surface and used to slowly inject 150 µL of AAV-CBA-fLuc/YFP or vehicle (1x PBS) into the vein. Gentle pressure was applied on the skin to achieve hemostasis and the incision was closed with the tissue adhesive (Vetbond, 3 M animal care products, USA). 1 × 1013 vg/kg body weight per mouse was injected in a total volume of 150 µL. Meloxicam (OstiLox, VETone, UK) at 0.5 mg/kg was injected subcutaneously as an analgesic for 72 h post-surgery. Animals were monitored carefully post-surgery according to IACUC instructions.

Intrathecal injection (IT)

For intrathecal injections, mice were anesthetized as mentioned above. Hair was removed from a small area on the lower back and scrubbed. A Hamilton syringe (26 gauge) was used to deliver the AAV (1 × 1012 vg/kg body weight per mouse, this dosage was used due to injection volume limitation) directly by lumbar puncture (between the fifth lumbar (L5) and the sixth lumbar (L6) vertebrae) in a total volume of 10 µL [33–36]. Male and female cohorts were injected for both capsids separately as mentioned above.

Intracerebroventricular injection (ICV)

For bilateral ICV injections, mice were anesthetized, hair was removed from the area between the ears, the head was fixed into the stereotaxic apparatus and scrubbed. A small incision was made, a T-shaped subcutaneous junction (bregma) was identified, a 26 gauge Hamilton needle attached to the apparatus was adjusted to that point, and subsequently the apparatus values for dorsoventral axis were set to zero. The needle was directed to the lateral ventricles: -0.5 mm in the anteroposterior axis, ± 1 mm in the mediolateral axis, and − 2.3 mm in the dorsoventral axis (~ 2 months old mouse coordinated according to Allen Brain Atlas). Once the needle was placed inside the ventricle, 5 µL of AAV-CBA-fLuc/YFP or vehicle (1x PBS) was injected slowly into the ventricle with a flow rate of 1 µL per minute to enable further diffusion [37]. Before slow withdrawal of the needle, there was a 2 min wait time to ensure complete diffusion of the injected fluid and no back-flow of the delivered virus. The other hemisphere was injected using the same procedure. The total injected AAV dose was 1 × 1012 vg/kg body weight per mouse (this dosage was used due to injection volume limitations using this delivery route in mice). The incision was closed with tissue adhesive (Vetbond, 3 M animal care products, USA), and meloxicam (OstiLox, VETone, UK) at 0.5 mg/kg was injected subcutaneously as an analgesic for 72 h post-surgery. Animals were monitored carefully post-surgery according to IACUC instructions.

In vivo live imaging

Two weeks following AAV administration, in vivo imaging was performed to monitor luciferase expression in live animals. The mice were administered with D-luciferin (#770504, IVISbrite D-LuciferinRediJect, PerkinElmer, USA) through intra-peritoneal (IP) injections at a dose of 150 mg/kg of body weight. After 15 min, mice were subjected to anesthesia (isoflurane inhalation) followed by bioluminescence imaging analysis using an in vivo optical imaging system (IVIS100 IVIS® Imaging System, PerkinElmer, USA). Raw images containing raw data were then analyzed in M3Vision software (Living Image Software, PerkinElmer), using the freehand tool to obtain total luciferase signals from each organ. Data were exported in photons (ph)/s/cm2/steradian unit and displayed as a pseudo-color overlay onto the animal image, using a rainbow color scale.

AAV vector genome (vg) determination

AAV vg copy numbers from various mouse tissues were determined as previously described [31, 32] by qPCR after extraction of total genomic DNA (gDNA) using DNeasy Blood and Tissue kit (#69506, Qiagen, Germany). Tissues were mechanically homogenized using a bead basher (BenchMark) with the kit lysis buffer. gDNA was isolated according to manufacturer instructions. Vg content in each tissue was determined using 100 ng total DNA using the qPCR method on the Applied Biosystems QuantStudio 3 thermal cycler and a Taqman probe specific for the luciferase reporter sequence (Assay ID: Mr03987587_mr, Thermo). Luciferase plasmid DNA dilutions with known copy number were used to create a standard curve to extrapolate absolute copy numbers in the tissue sample gDNA [38, 39].

Transcript analysis

Total RNA was isolated from mouse tissues using the Quick-RNA MiniPrep kit (#R1055, Zymo Research, USA) according to manufacturer’s instructions. The RNA kit includes a gDNA removal step. 300 ng of total gDNA-free-RNA was used for cDNA synthesis using the High-Capacity RNA-to-cDNA Kit (#4388950, Applied Biosystems, USA). This cDNA product served as the template for qPCR with luciferase probes (Assay ID: Mr03987587_mr, Thermo, USA) and the Applied Biosystems QuantStudio 3 thermal cycler. Ribosomal RNA 18s amplification (Assay ID: Mm03928990_g1, Thermo, USA) on the same cDNA was used as an internal control. Fold change in luciferase transcripts was calculated using the ΔΔCT method.

Luciferase assay

The frozen tissues (~ 25 mg) were homogenized in 400 µL of 1x reporter lysis buffer (#E1501 kit, Promega), and the lysates underwent 3 freeze thaw cycles (-80°C to 37 °C). The samples were centrifuged for 3 min. at 10,000 x g and supernatants were collected for the assay. In a 96 well plate (white bottom) 20 µL lysate was mixed with 50 µL Luciferase Assay Reagent (#E1501 kit, Promega) (as per the manufacturer’s instructions). The samples were run in triplicates and luminescence was measured with a 10,000ms integration time using the SpectraMax i3x plate reader (Molecular Devices).

Immunohistochemistry

Animals used for immunohistochemistry studies were euthanized by perfusion fixation as previously described [40, 41]. Mice were anaesthetized with isoflurane and perfused with sterile 1x PBS (pH 7.4) followed by a fixative (4% paraformaldehyde (PFA) in 1x PBS). Tissues were removed post fixation and placed in 4% PFA for 12 h overnight. The next day, the tissues were dehydrated and embedded into paraffin blocks. Sections were cut at 7 μm thickness and mounted onto pre-charged slides (#12-550-15 Superfrost Plus slides, Fisher Scientific, USA). For immuno-fluorescence (IF), tissue sections were rehydrated in 100% xylene, ethanol gradient (100%, 70%, 50%), and then water. Sections were permeabilized for 30 min at room temperature in 1x PBS containing 0.3% Triton X-100 and then incubated for 1 h in blocking solution (1x PBS containing 3% BSA, 2% normal donkey serum, and 0.15% Triton X-100). The same blocking reagent was used to prepare primary antibody dilutions which were incubated on samples overnight at 4 °C. The primary antibodies used include: mouse monoclonal anti-GFP/YFP 1:50 (#A11121, Invitrogen), (specificity was confirmed by lack of labeling in the vehicle treatment group); rabbit anti-NeuN 1:100 (#26975-I-AP, Proteintech), rabbit anti-GFAP 1:100 (#NB300-141, Novus Biologicals), rabbit anti-OLIG2 1:100 (#13999-1-AP, Proteintech). After a 5-minute 1x PBS rinse, sections were incubated for 1 h at room temperature with appropriate combinations of Alexa Fluor (1:500, AF568 goat anti-rabbit #A11036 and AF488 goat anti-mouse #A11029, Invitrogen) conjugated secondary antibodies (Life Technologies, Invitrogen). Sections were rinsed again in 1x PBS. Following the final rinses, sections were cover-slipped using a mounting solution containing DAPI (#P36962, ProLong Diamond Antifade Mountant, Invitrogen). Tissues from 1x PBS sham-injected mice were processed in parallel with the AAV-CBA-fLuc/YFP treated tissues and were included in all immunohistochemical experiments to control for non-specific staining of the YFP antibody.

Microscopy and image analysis

Images were collected on a Leica DM5500 B epi-fluorescent microscope with LAS-X software. For comparisons of tissues from ICV, IT, and IV injected mice, images were collected using the same microscope setting with a few exceptions where adjustments were necessary to allow detection of labeling in IT treated tissues or avoid saturation in ICV and IV treated tissues. Similarly, image adjustments for contrast, brightness, and color were performed in parallel for all delivery routes and treated tissues. For each mouse tissue, 5 non-overlapping images (2 from the cortex region, 2 from the hippocampus region, and 1 from the thalamus region from each brain slice) were taken from each of 3 tissue sections (brain slices). These were then evaluated by a trained, blinded observer. Different cell types in the brain were identified based on visualization with cell-type specific antibodies, and only cells with visible nuclei were counted. Total numbers of YFP positive cells were counted using the cell counter plugin in Image J software. The percentage of YFP positive cells were calculated from the total number of each cell type.

Statistical analysis

The data are expressed as mean or percentage ± standard error of the mean (SEM) from at least three animals unless indicated otherwise. For in vivo mouse imaging experiments, 8 mice were analyzed (front and back for 16 total data points) per treatment. For vgs, RNA, and luciferase assays, tissues from 6 mice were used in each group. For all IF studies, tissues from three different animals were analyzed. All the bar graph results are shown as mean ± SEM. No data were excluded from analyses. For determining the cell type counting with immunofluorescence assay images, the study investigators A.L.D and A.H. were blinded to treatment groups using codes generated by an independent investigator (M.C.). Five male and five female mice were used for each AAV delivery cohort. Comparisons were made using one-way analysis of variance (ANOVA) followed by a Bonferroni post-hoc test or by a two-tailed student t-test unless otherwise indicated. In figure legends, n indicates the number of animals used in the study (biological replicates). P values were calculated by the indicated statistical tests using GraphPad Prism (v.10.4.0) software.

Results

For all in vivo studies to assess the biodistribution of AAV9 and AAV-DJ, we used a ubiquitous Chicken β-actin (CBA) promoter to drive the expression of a firefly luciferase (fLuc) fused to a yellow fluorescent protein (YFP). This combination of promoter and transgene allowed for a versatile and highly sensitive evaluation of CNS expression for comparisons of each capsid using the intravenous (IV), intrathecal (IT), and intracerebroventricular (ICV) delivery routes in healthy wild-type FVB/NJ mice. For the ICV and IT routes, each mouse received 1 × 1012 vg/kg of either AAV9-CBA-fLuc/YFP, AAV-DJ-CBA-fLuc/YFP, or an equivalent volume of 1x PBS (for injection controls). For the IV route, each mouse received 1 × 1013 vg/kg of either AAV9-CBA-fLuc/YFP, AAV-DJ-CBA-fLuc/YFP, or an equivalent volume of 1x PBS (Fig. 1A). No difference between males and females was observed in any cohort. Mice from all cohorts were imaged for detection of luciferase mediated bioluminescence at three, seven, and nine weeks post-AAV administration (Fig. 1B).

Fig. 1 Experimental overview of capsid and delivery route comparisons. (A) WT FVBN/J mice at ~ 6 weeks of age were injected via intracerebroventricular (ICV), intrathecal (IT), or jugular vein (IV) injections with AAV9 or AAV-DJ to deliver a luciferase - yellow fluorescent protein (YFP) fusion protein. (B) Mice were evaluated throughout the study through non-invasive luciferase live imaging at the end of weeks 3 (I), 7 (II) and 9 (III). Nine weeks after AAV delivery, six mice (3 males and 3 females) were euthanized for DNA, RNA, and protein analysis and four mice (2 males and 2 females) for histological studies

Bioluminescence was detected from all AAV9 and AAV-DJ treated mice throughout every imaging session. As our goal was to primarily target the CNS, head/body radiance ratios were determined to provide relative biodistribution of expression information. Mice from both the ICV and IT AAV-DJ cohorts displayed a significant increase in relative head/body ratios at nine weeks as compared to those treated with AAV9 using the same delivery routes (Fig. 2A-D, Supp. Figure 1). In comparison, mice from the IV delivery route that were administered AAV9 displayed significantly higher head/body ratios at nine weeks as compared to those in the AAV-DJ cohort (Fig. 2F).

Fig. 2 Visualization and quantification of differential Luciferase expression patterns using IVIS whole-body live bioluminescence imaging in WT FVBN/J mice. 1 × 1012 vg/kg (ICV or IT) or 1 × 1013 vg/kg (IV) of AAV (AAV-CBA-fLuc/YFP) encoding the luciferase transgene was delivered into 6 week old mice via (A) ICV, C) IT, or E) IV administrations. Luciferase expression levels were detected by injecting luciferin substrate 15 min prior to bioluminescence imaging at 3, 7, and 9 weeks after vector administrations. Representative images of two mice from the AAV9 and AAV-DJ groups for Week 9 (post AAV delivery) are shown. Mouse 1 located on the right side of each image is the no virus control. Luciferase intensities from both the dorsal and ventral sides of each animal were obtained and head to body ratios were calculated and presented in the graphs (B) ICV, D) IT and F) IV. There are 16 data points from a total of 8 mice per cohort. The data are displayed as mean values ± SEM (N = 8 mice per group; *p < 0.05, ***p < 0.001, ns- not significant based upon unpaired two-tailed t-tests)

To quantify both the efficiency of gene transfer to various regions of the CNS and de-targeting of liver and kidney, full necropsies were performed on six mice from each cohort at nine weeks post-AAV administration. gDNA was isolated and AAV vector genome (vg) biodistribution was determined across the following brain regions: hippocampus, hypothalamus, cerebellum, and cortex, as well as spinal cord, liver, and kidney (Fig. 3). Using the IT and ICV routes, vg levels in the AAV-DJ cohorts were significantly higher than those from AAV9 cohorts in the hippocampus, hypothalamus, cerebellum, cortex, and spinal cord (Fig. 3A-E). In contrast, IT administration of AAV9 resulted in significantly higher levels of vgs in the off-target liver and kidney while ICV administration showed no differences between the two capsids (Fig. 3F, G). Using the IV delivery route, mice in the AAV9 cohort displayed significantly higher vg levels in the hypothalamus, cerebellum, and cortex as well as in the off-target organs liver and kidney as compared to AAV-DJ. IV delivery with the AAV-DJ capsid resulted in significantly higher vg levels in the hippocampus and spinal cord as compared to AAV9.

Fig. 3 AAV vector genome (vg) estimations in tissues of interest. gDNA was isolated and luciferase transgene vg numbers were calculated per ng of gDNA for (A-E) neurological tissues (hippocampus, hypothalamus, cortex, cerebellum, spinal cord) and off-target tissues F) liver and G) kidney. Data are presented as mean ± SEM of the values from six mice (*p < 0.05, **p < 0.01, ***p < 0.001, ns- not significant based upon unpaired two-tailed t-tests)

To further examine the efficiency of gene delivery by AAV-DJ and AAV9, luciferase gene transcription levels were assessed in the CNS and off-target organs. Total RNA was isolated from each tissue and luciferase transcription levels were assessed by quantitative PCR. The hippocampus, cerebellum, cortex, and spinal cord from the IT groups demonstrated significantly higher transcription levels following delivery with AAV-DJ whereas the hypothalamus, liver, and kidney had higher levels following delivery with AAV9 (Fig. 4A-G). The hippocampus, hypothalamus, cerebellum, spinal cord, and cortex from the ICV group all demonstrated significantly higher transcription levels following delivery with AAV-DJ whereas the liver and kidney showed no significant differences in expression levels between AAV-DJ and AAV9. Every neurological tissue analyzed except the cerebellum showed significantly higher expression following the use of IV administered AAV9 (Fig. 4A-E). However, both off-target organs (liver and kidney) also showed significantly higher expression levels with AAV9 (Fig. 4F, G).

Fig. 4 Luciferase transgene transcript levels in tissues of interest. Total RNA was isolated, converted to cDNA, and fold changes in luciferase mRNA transcript expression levels were calculated as compared to no virus controls for (A-E) neurological tissues (hippocampus, hypothalamus, cortex, cerebellum, spinal cord) and off-target tissues F) liver and G) kidney. Data are presented as mean ± SEM of the values from six mice (*p < 0.05, **p < 0.01, ***p < 0.001, ns- not significant based upon unpaired two-tailed t-tests)

Luciferase activity assays were used to quantify relative luciferase protein levels among organs and cohorts. Relative light units (RLUs) were normalized to the amount of total protein for each respective sample. The hippocampus, cerebellum, cortex, and spinal cord from the IT groups demonstrated significantly higher luciferase activity levels following delivery with AAV-DJ whereas the hypothalamus, liver, and kidney had higher levels following delivery with AAV9 (Fig. 5A-G). The hippocampus, hypothalamus, cerebellum, cortex, and spinal cord from the ICV group all demonstrated significantly higher luciferase activity levels following delivery with AAV-DJ, whereas the liver showed higher levels with AAV9 and the kidney showed no significant differences in expression levels between AAV-DJ and AAV9 (Fig. 5A-G). Every neurological tissue analyzed except the spinal cord showed significantly higher activity levels following the use of IV administered AAV9 (Fig. 5A-E). Both off-target organs (liver and kidney) also showed significantly higher levels with AAV9 (Fig. 5F, G).

Fig. 5 Luciferase activity assays in tissues of interest. Relative luciferase activities were measured and normalized to total protein concentrations and presented as fold changes in relative light units (RLUs) were calculated as compared to no virus controls for (A-E) neurological tissues (hippocampus, hypothalamus, cortex, cerebellum, spinal cord) and off-target tissues F) liver and G) kidney. Data are presented as mean ± SEM of the values from six mice (*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, ns- not significant based upon unpaired two-tailed t-tests)

Immunofluorescence (IF) staining was performed to identify differences in the ability of AAV9 and AAV-DJ to transduce specific neurological cell types. Co-immunostaining to detect YFP transgene expression and molecular markers for neurons (neuronal nuclei, NeuN), oligodendrocytes (olig2), and astrocytes (glial fibrillary acidic protein, GFAP) was performed on fixed brain slices from three mice representing each cohort. To facilitate quantitative evaluations of gene transfer efficacies between cohorts, the numbers of YFP/NeuN, YFP/olig2, and YFP/GFAP double-positive cells among the total number of neurons, oligodendrocytes, or astrocytes (respectively) were determined following imaging of coronal mouse brain sections (Supp. Figures 2, 3, 4, and 5).

Both the AAV9-CBA-fLuc/YFP and AAV-DJ-CBA-fLuc/YFP vectors yielded a similar general distribution of expression in neurons across brain regions (Supp. Figure 3and Fig. 6). Following ICV administrations, YFP expression was detected in 5.32% ± 3.98% (AAV9) and 11.77% ± 8.93% (AAV-DJ) of NeuN + cells (Fig. 6A). Following IT administrations, YFP expression was detected in 5.07% ± 2.83% (AAV9) and 6.50% ± 5.60% (AAV-DJ) of NeuN + cells (Fig. 6B). Following IV administrations, YFP expression was detected in 8.43% ± 3.21% (AAV9) and 5.46% ± 2.16% (AAV-DJ) of NeuN + cells (Fig. 6C).

Fig. 6 Relative transduction of neurons between cohorts. YFP transgene expression was compared to a neuronal cell marker (NeuN) and co-localization was quantified across cohorts through blinded analysis. Representative immunofluorescence images (from the cortex region as indicated in the brain overview image on the left) from each cohort (A) ICV, (B) IT, and (C) IV are provided. For each mouse tissue, five non-overlapping images were acquired from across each of three tissue sections, and evaluated by a trained, blinded observer. The percentages of YFP+/NueN+ cells are presented in the right-hand panels. Scale bars = 100 μm. The white box indicates the zoomed-in portion of the image that is displayed to the right of each row of images

Both the AAV9-CBA-fLuc/YFP and AAV-DJ-CBA-fLuc/YFP vectors yielded a similar general distribution of expression in oligodendrocytes across brain regions (Supp. Figure 4and Fig. 7). Following ICV administrations, YFP expression was detected in 12.19% ± 7.18% (AAV9) and 19.61% ± 7.88% (AAV-DJ) of olig2+ cells (Fig. 7A). Following IT administrations, YFP expression was detected in 16.45% ± 9.01% (AAV9) and 14.32% ± 5.48% (AAV-DJ) of olig2 + cells (Fig. 7B). Following IV administrations, YFP expression was detected in and 16.82% ± 10.49% (AAV9) and 9.92% ± 5.13% (AAV-DJ) of olig2+ cells (Fig. 7C).

Fig. 7 Relative transduction of oligodendrocytes between cohorts. YFP transgene expression was compared to an oligodendrocyte cell marker (OLIG2) and co-localization was quantified across cohorts through blinded analysis. Representative immunofluorescence images (from the hippocampus region indicated in the brain overview image on the left) from each cohort (A) ICV, (B) IT, and (C) IV are provided. For each mouse tissue, five non-overlapping images were acquired from across each of three tissue sections, and evaluated by a trained, blinded observer. The percentages of YFP+/OLIG2+ cells are presented in the right-hand panels. Scale bars = 100 μm. The white box indicates the zoomed-in portion of the image that is displayed to the right of each row of images

Both the AAV9-CBA-fLuc/YFP and AAV-DJ-CBA-fLuc/YFP vectors yielded a similar general distribution of expression in astrocytes across brain regions (Supp. Figure 5 and Fig. 8). Following ICV administrations, YFP expression was detected in 14.15% ± 4.28% (AAV9) and 17.49% ± 4.97% (AAV-DJ) of GFAP + cells (Fig. 8A). Following IT administrations, YFP expression was detected in 14.46% ± 6.13% (AAV9) and 15.89% ± 5.84% (AAV-DJ) of GFAP + cells (Fig. 8B). Following IV administrations, YFP expression was detected in 12.28% ± 5.40% (AAV9) and 16.92% ± 6.93% (AAV-DJ) of GFAP + cells (Fig. 8C).

Fig. 8 Relative transduction of neurons between cohorts. YFP transgene expression was compared to an astrocyte cell marker (GFAP) and the co-localization was quantified across cohorts through blinded analysis. Representative immunofluorescence images (from the hippocampus area as indicated in a brain overview image) from each cohort (A) ICV, (B) IT, and (C) IV are provided. For each mouse tissue, five non-overlapping images were acquired from across each of three tissue sections, and evaluated by a trained, blinded observer. The percentages of YFP+/GFAP+ cells are presented in the right-hand panels. Scale bars = 100 μm. The white box indicates the zoomed-in portion of the image that is displayed to the right of each row of images

Based upon these data, the AAV-DJ capsid transduces significantly more neurons, astrocytes, and oligodendrocytes than the AAV9 capsid when using the ICV administration route. No significant differences were observed between the ability of the two capsids to transduce neurons, astrocytes, or oligodendrocytes following IT administrations. In contrast, the IV administration data showed more variation with the AAV9 capsid transducing significantly more neurons, AAV-DJ transducing significantly more astrocytes, and no significant difference observed in the ability of these capsids to transduce oligodendrocytes.

To summarize our findings, we generated a heat map that included a score for each experimental result based on our goal of optimizing transduction of neurological tissue and de-targeting the liver and kidney (Fig. 9). This heat map indicates that overall, the AAV-DJ capsid provides a more desirable outcome regardless of the delivery route used.

Fig. 9 A heat map summarizing the AAV-mediated gene therapy capsid and delivery route comparison. Scoring criteria are indicated in the right-hand panel based on the statistical significance obtained in each assay as compared to the other capsid

Discussion

AAV vectors are being increasingly incorporated into the development of gene therapies for a wide variety of genetically inherited disorders due to their ability to efficiently transduce various cell types, including non-dividing cells with relatively minimal immunogenicity [42–45]. Several naturally occurring and engineered capsids have been evaluated for targeted gene delivery to specific tissues [43, 46, 47]. AAV9 has been found to have broad tropism for a variety of organs and is the gene delivery vehicle used in an FDA-approved therapy for SMA [7] due to its ability to cross the blood brain barrier and efficiently transduce the CNS in children up to two years of age. Despite the overall clinical success with this therapy, there remain challenges due to the tendency of human patients to have high levels of pre-existing antibodies against natural occurring serotypes such as AAV9. Delivery of AAV9 in the presence of high pre-existing antibody levels results in an immune response that attacks the AAV9 and diminishes the therapeutic effect. Therefore, many investigators are working to develop engineered capsids that evade pre-existing neutralizing antibodies or induce milder immune responses, in the hope that this will allow for more sustained transgene expression and therapeutic benefit at lower doses [48–50].

The AAV-DJ serotype used in our studies was developed and identified through screening pools of hybrid AAV vectors. It was generated from screened combinations of five natural serotypes (AAV 2, 4, 5, 8, and 9) [20]. The screening resulted in an AAV 2/8/9 chimera (AAV-DJ) that differs from its closest AAV serotype relative (AAV2) by 60 amino acids. Several previous studies have shown that AAV-DJ is highly efficient in vivo [51–54]. Recently, a non-human primate study demonstrated that AAV-DJ successfully achieved broad transduction throughout the brain [21]. A careful assessment of AAV-DJ transduction as compared to AAV9 in mice was needed to provide a strong rationale for testing this capsid as a gene delivery vehicle to treat neurological disorders in small and large animal models, as well as evaluating its efficacy in future human clinical trials.

AAV-DJ exhibits robust transduction efficiency in both in vitro and in vivo as compared to several naturally occurring AAV serotypes, including AAV2 and AAV8 [20, 55, 56]. The enhanced transduction profile of AAV-DJ can be attributed to its capsid properties, including altered receptor binding and cellular trafficking mechanisms [20, 23]. Our hypothesis that AAV-DJ would provide more on-target CNS expression and less expression in the liver and kidney turned out to be true, when directly compared to results using the same doses and delivery routes for AAV9 (Fig. 9).

We compared the transduction efficiency of AAV9 and AAV-DJ using three delivery routes (IV, IT, and ICV) to characterize differences and similarities in their abilities to transduce specific regions of the brain, the spinal cord, specific neuronal cell types of interest, and off target organs (liver and kidney). A dose of 1 × 1013 vg/kg was used for IV administrations of these vectors as this aligns well with typical systemic doses used in previous AAV mediated gene therapy studies [31, 57]. A lower dose of 1 × 1012 vg/kg was used for both IT and ICV injections due to volume limitations using these delivery routes [58]. We remained within the typical dose range for each of these delivery routes in mice.

Improved targeting efficiency of neurological gene therapies will help to address the high liver innate and adaptive immune responses that are often observed even in successful AAV gene therapies [26, 59]. Our use of the ubiquitous chicken-β-actin (CBA) promoter to express a luciferase-YFP fusion construct enabled us to noninvasively detect in vivo luciferase activity using IVIS bioluminescence imaging and conduct longitudinal assessments of general transgene expression on live animals [60]. This methodology is easily accessible and simple to perform to gain a broad and general sense of transgene expression through detection of the extent of bioluminescence using a gradient generated from selected regions of interest [61]. This construct also enabled us to perform confirmatory luciferase assays on harvested tissues, and to conduct more precise IF expression analyses of specific cell types using an antibody that recognized YFP on tissue sections.

Although we used a ubiquitous promoter for these studies, promoters do provide another important level of control over vector transgene expression [62]. The use of cell-type specific promoters such as human synapsin (hSYN) can restrict transgene expression profiles to specific cell types or tissues [63, 64]. Other studies suggest that promoter-capsid interactions can also influence in vivo expression [65, 66]. Future studies designed to pair the AAV-DJ capsid and optimal delivery route with promoter comparisons will further refine CNS targeted AAV-mediated gene therapy strategies.

The mouse strain used can influence the transduction profiles of AAV capsids. One example of this is the AAV-PHP.B family of capsids that requires the Ly6A receptor for efficient transduction and thus, must be used with mice on the C57/BL6 background strain [67]. For this study, we used wild-type FVB/NJ mice and our results were similar to those previously observed in a non-human primate study evaluating neuronal transduction [21]. Thus, as our results are consistent across at least two different species, we are confident that they are not an artifact resulting from the FVB/NJ mouse strain.

One limitation to our study is the duration of these experiments. This study was conducted using a set timeline of nine weeks that is significantly shorter than what would typically be desired in humans where the goal would be to provide therapeutic expression for the lifetime of the patient. While our goal for this study was to establish an optimal AAV capsid and delivery route, other studies will be needed to establish durability of expression based upon these and other factors such as promoter usage and dose. Subsequent studies would also benefit from the use of a large animal model that more accurately represents human neurological tissue size and physiology. Recent developments for gene editing in swine allows for the generation of pig genetic models that more accurately mimic human physiology, anatomy, and lifespan [68]. Swine models more accurately match the size and complexity of the human brain and will be instrumental for the optimization of doses and AAV volumes in the future. Future long-term studies designed to establish the durability of AAV-DJ based or other novel AAV capsids can be performed in swine models to support translation into human clinical trials.

In general, the RNA transcript and protein expression levels we observed were similar to those found in the vg data. Subtle differences are likely related to variances in the distribution of data between cohorts due to factors such as assay sensitivity, post-transcriptional modifications, RNA/protein stability, and translational efficiency [69]. The cumulative data depicted in our heat map show a clear distinction between the two capsids’ neurological transduction efficiencies when using the ICV or IT delivery routes. In contrast, cumulative scores between the two capsids following use of the IV delivery route are similar albeit the capsids demonstrated distinct attributes and limitations. For example, AAV9 (IV) transduces many desirable target organs along with off-target organs (live and kidney) while AAV-DJ profiles are lower in target organs but much lower in off-target organs.

In conclusion, our study indicates that AAV-DJ is superior for targeting the brain and spinal cord while concurrently de-targeting liver and kidney in mice. These findings enable the selection of a combined optimal capsid and administration route for various CNS disease-specific therapeutic targets. This study also establishes a foundation upon which future studies can be designed to test AAV-DJ for use in gene therapies targeting the CNS, evaluate AAV-DJ capsid modifications for improved neuronal transduction, and perform promoter comparisons to further improve the efficacy of gene therapies.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary Material 1

Acknowledgements

This work was supported by the resources and staff at the University of Minnesota University Imaging Centers (UIC: SCR_020997). Thank you to the CFI/ITN Imaging Core and Dr. Jason Mitchell for the microscope training and to Alexia Hang and Frances Sehneah for assistance in RNA and gDNA isolations. Figure 1 was created with the help of BioRender.com.

Author contributions

M.C. and C.A.P. designed the experiments, analyzed the data, and wrote the manuscript with input and editing from P.B.K., G.A., J.A.T, and A.L.D. Virus production, purification and its quality controls were performed by O.F.D. and G.A. AAV administrations and IVIS imaging were performed by M.C., A.L.D. and F.K. M.C. and A.L.D. performed quantitative PCRs and luciferase assays. M.C. and A.L.D. performed histology preparations and M.C. performed immunofluorescence assays. A.L.D., A.H. quantified the immunofluorescence assays blinded. All authors reviewed a draft of the manuscript and provided input.

Funding

This work was supported by the US Food and Drug Administration/Center for Biologics Evaluation and Research, Contract/Grant Number: R01FD007483 (C.A.P. and G.A. MPI), as well as generous support from the Viljem Julijan Association for Children with Rare Diseases.

Declarations

Conflict of interest

Authors declare no conflict of interest.

Abbreviations

AAV Adeno-associated virus

ANOVA Analysis of Variance

CBA Chicken β-actin

cDNA complementary DNA

CNS Central Nervous System

FDA Food and Drug Administration

fLuc Firefly luciferase

gDNA genomic DNA

GFAP Glial fibrillary acidic protein (intermediate filament-III)

HEK293 Human Embryonic Kidney cell line

ICV Intracerebroventricular

IF Immunofluorescence

IP Intraperitoneal

IT Intrathecal

ITR Inverted terminal repeats

IV Intravenous

NeuN Neuronal specific nuclear protein (Fox-3, Rbfox3, or Hexaribonucleotide Binding Protein-3)

OLIG2 Oligodendrocyte transcription factor 2

PFA Paraformaldehyde

PBS Phosphate buffered saline

qPCR Quantitative Polymerase Chain Reaction

Rep/Cap Replication and Capsid protein coding

RLUs Relative Light Units

SEM Standard error of mean

SMA SMA (Spinal Muscular Atrophy)

Vg Vector genome

WT Wild-type

YFP Yellow Fluorescent Protein

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
==== Refs
References

1. Mingozzi F High KA Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges Nat Rev Genet 2011 12 341 55 10.1038/nrg2988 21499295
Mingozzi F, High KA. Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges. Nat Rev Genet. 2011;12:341–55.21499295 10.1038/nrg2988
2. Manno CS Chew AJ Hutchison S Larson PJ Herzog RW Arruda VR Tai SJ Ragni MV Thompson A Ozelo M AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B Blood 2003 101 2963 72 10.1182/blood-2002-10-3296 12515715
Manno CS, Chew AJ, Hutchison S, Larson PJ, Herzog RW, Arruda VR, Tai SJ, Ragni MV, Thompson A, Ozelo M, et al. AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. Blood. 2003;101:2963–72.12515715 10.1182/blood-2002-10-3296
3. Rangarajan S Walsh L Lester W Perry D Madan B Laffan M Yu H Vettermann C Pierce GF Wong WY AAV5-Factor VIII gene transfer in severe Hemophilia A N Engl J Med 2017 377 2519 30 10.1056/NEJMoa1708483 29224506
Rangarajan S, Walsh L, Lester W, Perry D, Madan B, Laffan M, Yu H, Vettermann C, Pierce GF, Wong WY, et al. AAV5-Factor VIII gene transfer in severe Hemophilia A. N Engl J Med. 2017;377:2519–30.29224506 10.1056/NEJMoa1708483
4. Miesbach W Meijer K Coppens M Kampmann P Klamroth R Schutgens R Tangelder M Castaman G Schwable J Bonig H Gene therapy with adeno-associated virus vector 5-human factor IX in adults with hemophilia B Blood 2018 131 1022 31 10.1182/blood-2017-09-804419 29246900
Miesbach W, Meijer K, Coppens M, Kampmann P, Klamroth R, Schutgens R, Tangelder M, Castaman G, Schwable J, Bonig H, et al. Gene therapy with adeno-associated virus vector 5-human factor IX in adults with hemophilia B. Blood. 2018;131:1022–31.29246900 10.1182/blood-2017-09-804419
5. George LA Sullivan SK Giermasz A Rasko JEJ Samelson-Jones BJ Ducore J Cuker A Sullivan LM Majumdar S Teitel J Hemophilia B Gene Therapy with a high-specific-activity factor IX variant N Engl J Med 2017 377 2215 27 10.1056/NEJMoa1708538 29211678
George LA, Sullivan SK, Giermasz A, Rasko JEJ, Samelson-Jones BJ, Ducore J, Cuker A, Sullivan LM, Majumdar S, Teitel J, et al. Hemophilia B Gene Therapy with a high-specific-activity factor IX variant. N Engl J Med. 2017;377:2215–27.29211678 10.1056/NEJMoa1708538
6. Nathwani AC Tuddenham EG Rangarajan S Rosales C McIntosh J Linch DC Chowdary P Riddell A Pie AJ Harrington C Adenovirus-associated virus vector-mediated gene transfer in hemophilia B N Engl J Med 2011 365 2357 65 10.1056/NEJMoa1108046 22149959
Nathwani AC, Tuddenham EG, Rangarajan S, Rosales C, McIntosh J, Linch DC, Chowdary P, Riddell A, Pie AJ, Harrington C, et al. Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med. 2011;365:2357–65.22149959 10.1056/NEJMoa1108046
7. Bevan AK Duque S Foust KD Morales PR Braun L Schmelzer L Chan CM McCrate M Chicoine LG Coley BD Systemic gene delivery in large species for targeting spinal cord, brain, and peripheral tissues for pediatric disorders Mol Ther 2011 19 1971 80 10.1038/mt.2011.157 21811247
Bevan AK, Duque S, Foust KD, Morales PR, Braun L, Schmelzer L, Chan CM, McCrate M, Chicoine LG, Coley BD, et al. Systemic gene delivery in large species for targeting spinal cord, brain, and peripheral tissues for pediatric disorders. Mol Ther. 2011;19:1971–80.21811247 10.1038/mt.2011.157
8. Smith BK Collins SW Conlon TJ Mah CS Lawson LA Martin AD Fuller DD Cleaver BD Clement N Phillips D Phase I/II trial of adeno-associated virus-mediated alpha-glucosidase gene therapy to the diaphragm for chronic respiratory failure in pompe disease: initial safety and ventilatory outcomes Hum Gene Ther 2013 24 630 40 10.1089/hum.2012.250 23570273
Smith BK, Collins SW, Conlon TJ, Mah CS, Lawson LA, Martin AD, Fuller DD, Cleaver BD, Clement N, Phillips D, et al. Phase I/II trial of adeno-associated virus-mediated alpha-glucosidase gene therapy to the diaphragm for chronic respiratory failure in pompe disease: initial safety and ventilatory outcomes. Hum Gene Ther. 2013;24:630–40.23570273 10.1089/hum.2012.250
9. Mendell JR Al-Zaidy SA Rodino-Klapac LR Goodspeed K Gray SJ Kay CN Boye SL Boye SE George LA Salabarria S Current clinical applications of in vivo gene therapy with AAVs Mol Ther 2021 29 464 88 10.1016/j.ymthe.2020.12.007 33309881
Mendell JR, Al-Zaidy SA, Rodino-Klapac LR, Goodspeed K, Gray SJ, Kay CN, Boye SL, Boye SE, George LA, Salabarria S, et al. Current clinical applications of in vivo gene therapy with AAVs. Mol Ther. 2021;29:464–88.33309881 10.1016/j.ymthe.2020.12.007
10. Schnepp BC Clark KR Klemanski DL Pacak CA Johnson PR Genetic fate of recombinant adeno-associated virus vector genomes in muscle J Virol 2003 77 3495 504 10.1128/JVI.77.6.3495-3504.2003 12610125
Schnepp BC, Clark KR, Klemanski DL, Pacak CA, Johnson PR. Genetic fate of recombinant adeno-associated virus vector genomes in muscle. J Virol. 2003;77:3495–504.12610125 10.1128/JVI.77.6.3495-3504.2003
11. Clark KR Sferra TJ Lo W Qu G Chen R Johnson PR Gene transfer into the CNS using recombinant adeno-associated virus: analysis of vector DNA forms resulting in sustained expression J Drug Target 1999 7 269 83 10.3109/10611869909085510 10682906
Clark KR, Sferra TJ, Lo W, Qu G, Chen R, Johnson PR. Gene transfer into the CNS using recombinant adeno-associated virus: analysis of vector DNA forms resulting in sustained expression. J Drug Target. 1999;7:269–83.10682906 10.3109/10611869909085510
12. Salabarria SM, Corti M, Coleman KE, Wichman MB, Berthy JA, D’Souza P, Tifft CJ, Herzog RW, Elder ME, Shoemaker LR et al. (2024) Thrombotic microangiopathy following systemic AAV administration is dependent on anti-capsid antibodies. J Clin Invest, 134.
13. Jayandharan GR Aslanidi G Martino AT Jahn SC Perrin GQ Herzog RW Srivastava A Activation of the NF-kappaB pathway by adeno-associated virus (AAV) vectors and its implications in immune response and gene therapy Proc Natl Acad Sci U S A 2011 108 3743 8 10.1073/pnas.1012753108 21321191
Jayandharan GR, Aslanidi G, Martino AT, Jahn SC, Perrin GQ, Herzog RW, Srivastava A. Activation of the NF-kappaB pathway by adeno-associated virus (AAV) vectors and its implications in immune response and gene therapy. Proc Natl Acad Sci U S A. 2011;108:3743–8.21321191 10.1073/pnas.1012753108
14. Rogers GL Martino AT Aslanidi GV Jayandharan GR Srivastava A Herzog RW Innate Immune responses to AAV vectors Front Microbiol 2011 2 194 10.3389/fmicb.2011.00194 21954398
Rogers GL, Martino AT, Aslanidi GV, Jayandharan GR, Srivastava A, Herzog RW. Innate Immune responses to AAV vectors. Front Microbiol. 2011;2:194.21954398 10.3389/fmicb.2011.00194
15. Ronzitti G Gross DA Mingozzi F Human Immune responses to Adeno-Associated Virus (AAV) vectors Front Immunol 2020 11 670 10.3389/fimmu.2020.00670 32362898
Ronzitti G, Gross DA, Mingozzi F. Human Immune responses to Adeno-Associated Virus (AAV) vectors. Front Immunol. 2020;11:670.32362898 10.3389/fimmu.2020.00670
16. Fitzpatrick Z Leborgne C Barbon E Masat E Ronzitti G van Wittenberghe L Vignaud A Collaud F Charles S Sola S Influence of pre-existing anti-capsid neutralizing and binding antibodies on AAV Vector Transduction Mol Ther Methods Clin Dev 2018 9 119 29 10.1016/j.omtm.2018.02.003 29766022
Fitzpatrick Z, Leborgne C, Barbon E, Masat E, Ronzitti G, van Wittenberghe L, Vignaud A, Collaud F, Charles S, Sola S, M., et al. Influence of pre-existing anti-capsid neutralizing and binding antibodies on AAV Vector Transduction. Mol Ther Methods Clin Dev. 2018;9:119–29.29766022 10.1016/j.omtm.2018.02.003
17. Prasad S Dimmock DP Greenberg B Walia JS Sadhu C Tavakkoli F Lipshutz GS Immune responses and immunosuppressive strategies for Adeno-Associated Virus-based gene therapy for treatment of Central Nervous System disorders: current knowledge and approaches Hum Gene Ther 2022 33 1228 45 10.1089/hum.2022.138 35994385
Prasad S, Dimmock DP, Greenberg B, Walia JS, Sadhu C, Tavakkoli F, Lipshutz GS. Immune responses and immunosuppressive strategies for Adeno-Associated Virus-based gene therapy for treatment of Central Nervous System disorders: current knowledge and approaches. Hum Gene Ther. 2022;33:1228–45.35994385 10.1089/hum.2022.138
18. Sansone VA Pirola A Albamonte E Pane M Lizio A D’Amico A Catteruccia M Cutrera R Bruno C Pedemonte M Respiratory needs in patients with type 1 spinal muscular atrophy treated with Nusinersen J Pediatr 2020 219 223 e228224 10.1016/j.jpeds.2019.12.047 32035635
Sansone VA, Pirola A, Albamonte E, Pane M, Lizio A, D’Amico A, Catteruccia M, Cutrera R, Bruno C, Pedemonte M, et al. Respiratory needs in patients with type 1 spinal muscular atrophy treated with Nusinersen. J Pediatr. 2020;219:223–e228224.32035635 10.1016/j.jpeds.2019.12.047
19. Liguore WA Domire JS Button D Wang Y Dufour BD Srinivasan S McBride JL AAV-PHP.B Administration results in a Differential Pattern of CNS biodistribution in non-human Primates compared with mice Mol Ther 2019 27 2018 37 10.1016/j.ymthe.2019.07.017 31420242
Liguore WA, Domire JS, Button D, Wang Y, Dufour BD, Srinivasan S, McBride JL. AAV-PHP.B Administration results in a Differential Pattern of CNS biodistribution in non-human Primates compared with mice. Mol Ther. 2019;27:2018–37.31420242 10.1016/j.ymthe.2019.07.017
20. Grimm D Lee JS Wang L Desai T Akache B Storm TA Kay MA In vitro and in vivo gene therapy vector evolution via multispecies interbreeding and retargeting of adeno-associated viruses J Virol 2008 82 5887 911 10.1128/JVI.00254-08 18400866
Grimm D, Lee JS, Wang L, Desai T, Akache B, Storm TA, Kay MA. In vitro and in vivo gene therapy vector evolution via multispecies interbreeding and retargeting of adeno-associated viruses. J Virol. 2008;82:5887–911.18400866 10.1128/JVI.00254-08
21. Kondratov O Kondratova L Mandel RJ Coleman K Savage MA Gray-Edwards HL Ness TJ Rodriguez-Lebron E Bell RD Rabinowitz J A comprehensive study of a 29-capsid AAV library in a non-human primate central nervous system Mol Ther 2021 29 2806 20 10.1016/j.ymthe.2021.07.010 34298128
Kondratov O, Kondratova L, Mandel RJ, Coleman K, Savage MA, Gray-Edwards HL, Ness TJ, Rodriguez-Lebron E, Bell RD, Rabinowitz J, et al. A comprehensive study of a 29-capsid AAV library in a non-human primate central nervous system. Mol Ther. 2021;29:2806–20.34298128 10.1016/j.ymthe.2021.07.010
22. Asokan A Shen S Redirecting AAV vectors to extrahepatic tissues Mol Ther 2023 31 3371 5 10.1016/j.ymthe.2023.10.005 37805712
Asokan A, Shen S. Redirecting AAV vectors to extrahepatic tissues. Mol Ther. 2023;31:3371–5.37805712 10.1016/j.ymthe.2023.10.005
23. Zincarelli C Soltys S Rengo G Rabinowitz JE Analysis of AAV serotypes 1–9 mediated gene expression and tropism in mice after systemic injection Mol Ther 2008 16 1073 80 10.1038/mt.2008.76 18414476
Zincarelli C, Soltys S, Rengo G, Rabinowitz JE. Analysis of AAV serotypes 1–9 mediated gene expression and tropism in mice after systemic injection. Mol Ther. 2008;16:1073–80.18414476 10.1038/mt.2008.76
24. Mendell JR Al-Zaidy S Shell R Arnold WD Rodino-Klapac LR Prior TW Lowes L Alfano L Berry K Church K Single-dose gene-replacement therapy for spinal muscular atrophy N Engl J Med 2017 377 1713 22 10.1056/NEJMoa1706198 29091557
Mendell JR, Al-Zaidy S, Shell R, Arnold WD, Rodino-Klapac LR, Prior TW, Lowes L, Alfano L, Berry K, Church K, et al. Single-dose gene-replacement therapy for spinal muscular atrophy. N Engl J Med. 2017;377:1713–22.29091557 10.1056/NEJMoa1706198
25. Yang TY Braun M Lembke W McBlane F Kamerud J DeWall S Tarcsa E Fang X Hofer L Kavita U Immunogenicity assessment of AAV-based gene therapies: an IQ consortium industry white paper Mol Ther Methods Clin Dev 2022 26 471 94 10.1016/j.omtm.2022.07.018 36092368
Yang TY, Braun M, Lembke W, McBlane F, Kamerud J, DeWall S, Tarcsa E, Fang X, Hofer L, Kavita U, et al. Immunogenicity assessment of AAV-based gene therapies: an IQ consortium industry white paper. Mol Ther Methods Clin Dev. 2022;26:471–94.36092368 10.1016/j.omtm.2022.07.018
26. Duan D Lethal immunotoxicity in high-dose systemic AAV therapy Mol Ther 2023 31 3123 6 10.1016/j.ymthe.2023.10.015 37822079
Duan D. Lethal immunotoxicity in high-dose systemic AAV therapy. Mol Ther. 2023;31:3123–6.37822079 10.1016/j.ymthe.2023.10.015
27. Colon-Cortes Y Hasan MA Aslanidi G Intra-tracheal delivery of AAV6 vectors results in sustained transduction in murine lungs without genomic integration Gene 2020 763S 100037 10.1016/j.gene.2020.100037 34493365
Colon-Cortes Y, Hasan MA, Aslanidi G. Intra-tracheal delivery of AAV6 vectors results in sustained transduction in murine lungs without genomic integration. Gene. 2020;763S:100037.34493365 10.1016/j.gene.2020.100037
28. Krotova K Aslanidi G Modifiers of Adeno-Associated virus-mediated gene expression in implication for serotype-universal neutralizing antibody assay Hum Gene Ther 2020 31 1124 31 10.1089/hum.2020.074 32495655
Krotova K, Aslanidi G. Modifiers of Adeno-Associated virus-mediated gene expression in implication for serotype-universal neutralizing antibody assay. Hum Gene Ther. 2020;31:1124–31.32495655 10.1089/hum.2020.074
29. Pandya J Ortiz L Ling C Rivers AE Aslanidi G Rationally designed capsid and transgene cassette of AAV6 vectors for dendritic cell-based cancer immunotherapy Immunol Cell Biol 2014 92 116 23 10.1038/icb.2013.74 24217810
Pandya J, Ortiz L, Ling C, Rivers AE, Aslanidi G. Rationally designed capsid and transgene cassette of AAV6 vectors for dendritic cell-based cancer immunotherapy. Immunol Cell Biol. 2014;92:116–23.24217810 10.1038/icb.2013.74
30. Krotova K Yoshitomi K Caine H Aslanidi G Tumor antigen-loaded AAV vaccine drives protective immunity in a melanoma animal model Mol Ther Methods Clin Dev 2023 28 301 11 10.1016/j.omtm.2023.01.006 36851984
Krotova K, Yoshitomi K, Caine H, C. and, Aslanidi G. Tumor antigen-loaded AAV vaccine drives protective immunity in a melanoma animal model. Mol Ther Methods Clin Dev. 2023;28:301–11.36851984 10.1016/j.omtm.2023.01.006
31. Suzuki-Hatano S Saha M Rizzo SA Witko RL Gosiker BJ Ramanathan M Soustek MS Jones MD Kang PB Byrne BJ AAV-Mediated TAZ gene replacement restores mitochondrial and cardioskeletal function in Barth Syndrome Hum Gene Ther 2019 30 139 54 10.1089/hum.2018.020 30070157
Suzuki-Hatano S, Saha M, Rizzo SA, Witko RL, Gosiker BJ, Ramanathan M, Soustek MS, Jones MD, Kang PB, Byrne BJ, et al. AAV-Mediated TAZ gene replacement restores mitochondrial and cardioskeletal function in Barth Syndrome. Hum Gene Ther. 2019;30:139–54.30070157 10.1089/hum.2018.020
32. Pacak CA Suzuki-Hatano S Khadir F Daugherty AL Sriramvenugopal M Gosiker BJ Kang PB Cade WT One episode of low intensity aerobic exercise prior to systemic AAV9 administration augments transgene delivery to the heart and skeletal muscle J Transl Med 2023 21 748 10.1186/s12967-023-04626-1 37875924
Pacak CA, Suzuki-Hatano S, Khadir F, Daugherty AL, Sriramvenugopal M, Gosiker BJ, Kang PB, Cade WT. One episode of low intensity aerobic exercise prior to systemic AAV9 administration augments transgene delivery to the heart and skeletal muscle. J Transl Med. 2023;21:748.37875924 10.1186/s12967-023-04626-1
33. Hylden JL Wilcox GL Intrathecal substance P elicits a caudally-directed biting and scratching behavior in mice Brain Res 1981 217 212 5 10.1016/0006-8993(81)90203-1 6167328
Hylden JL, Wilcox GL. Intrathecal substance P elicits a caudally-directed biting and scratching behavior in mice. Brain Res. 1981;217:212–5.6167328 10.1016/0006-8993(81)90203-1
34. Cheng W Huang J Fu XQ Tian WY Zeng PM Li Y Luo ZG Intrathecal delivery of AAV-NDNF ameliorates disease progression of ALS mice Mol Ther 2023 31 3277 89 10.1016/j.ymthe.2023.09.018 37766430
Cheng W, Huang J, Fu XQ, Tian WY, Zeng PM, Li Y, Luo ZG. Intrathecal delivery of AAV-NDNF ameliorates disease progression of ALS mice. Mol Ther. 2023;31:3277–89.37766430 10.1016/j.ymthe.2023.09.018
35. Smirnov VT, Dubrovskaia FI, Kiseleva TI. (1978) [Action of dimethyldioxane on the generative function of experimental animals]. Gig Sanit, 16–8.
36. Hylden JL Wilcox GL Intrathecal morphine in mice: a new technique Eur J Pharmacol 1980 67 313 6 10.1016/0014-2999(80)90515-4 6893963
Hylden JL, Wilcox GL. Intrathecal morphine in mice: a new technique. Eur J Pharmacol. 1980;67:313–6.6893963 10.1016/0014-2999(80)90515-4
37. Taylor ZV Khand B Porgador A Monsonego A Eremenko E An optimized intracerebroventricular injection of CD4(+) T cells into mice STAR Protoc 2021 2 100725 10.1016/j.xpro.2021.100725 34401790
Taylor ZV, Khand B, Porgador A, Monsonego A, Eremenko E. An optimized intracerebroventricular injection of CD4(+) T cells into mice. STAR Protoc. 2021;2:100725.34401790 10.1016/j.xpro.2021.100725
38. Gray SJ, Choi VW, Asokan A, Haberman RA, McCown TJ, Samulski RJ. (2011) Production of recombinant adeno-associated viral vectors and use in in vitro and in vivo administration. Curr Protoc Neurosci, Chap. 4, Unit 4 17.
39. Jonasson R Jonsson B Nordlander R Orinius E Szamosi A Rate of progression of severity of valvular aortic stenosis Acta Med Scand 1983 213 51 4 10.1111/j.0954-6820.1983.tb03689.x 6829320
Jonasson R, Jonsson B, Nordlander R, Orinius E, Szamosi A. Rate of progression of severity of valvular aortic stenosis. Acta Med Scand. 1983;213:51–4.6829320 10.1111/j.0954-6820.1983.tb03689.x
40. Vulchanova L Riedl MS Shuster SJ Buell G Surprenant A North RA Elde R Immunohistochemical study of the P2 × 2 and P2 × 3 receptor subunits in rat and monkey sensory neurons and their central terminals Neuropharmacology 1997 36 1229 42 10.1016/S0028-3908(97)00126-3 9364478
Vulchanova L, Riedl MS, Shuster SJ, Buell G, Surprenant A, North RA, Elde R. Immunohistochemical study of the P2X2 and P2X3 receptor subunits in rat and monkey sensory neurons and their central terminals. Neuropharmacology. 1997;36:1229–42.9364478 10.1016/S0028-3908(97)00126-3
41. Deverman BE Pravdo PL Simpson BP Kumar SR Chan KY Banerjee A Wu WL Yang B Huber N Pasca SP Cre-dependent selection yields AAV variants for widespread gene transfer to the adult brain Nat Biotechnol 2016 34 204 9 10.1038/nbt.3440 26829320
Deverman BE, Pravdo PL, Simpson BP, Kumar SR, Chan KY, Banerjee A, Wu WL, Yang B, Huber N, Pasca SP, et al. Cre-dependent selection yields AAV variants for widespread gene transfer to the adult brain. Nat Biotechnol. 2016;34:204–9.26829320 10.1038/nbt.3440
42. Sack BK Herzog RW Evading the immune response upon in vivo gene therapy with viral vectors Curr Opin Mol Ther 2009 11 493 503 19806497
Sack BK, Herzog RW. Evading the immune response upon in vivo gene therapy with viral vectors. Curr Opin Mol Ther. 2009;11:493–503.19806497
43. Wang D Tai PWL Gao G Adeno-associated virus vector as a platform for gene therapy delivery Nat Rev Drug Discov 2019 18 358 78 10.1038/s41573-019-0012-9 30710128
Wang D, Tai PWL, Gao G. Adeno-associated virus vector as a platform for gene therapy delivery. Nat Rev Drug Discov. 2019;18:358–78.30710128 10.1038/s41573-019-0012-9
44. Aguti S Malerba A Zhou H The progress of AAV-mediated gene therapy in neuromuscular disorders Expert Opin Biol Ther 2018 18 681 93 10.1080/14712598.2018.1479739 29781327
Aguti S, Malerba A, Zhou H. The progress of AAV-mediated gene therapy in neuromuscular disorders. Expert Opin Biol Ther. 2018;18:681–93.29781327 10.1080/14712598.2018.1479739
45. Ling Q Herstine JA Bradbury A Gray SJ AAV-based in vivo gene therapy for neurological disorders Nat Rev Drug Discov 2023 22 789 806 10.1038/s41573-023-00766-7 37658167
Ling Q, Herstine JA, Bradbury A, Gray SJ. AAV-based in vivo gene therapy for neurological disorders. Nat Rev Drug Discov. 2023;22:789–806.37658167 10.1038/s41573-023-00766-7
46. Gao G Vandenberghe LH Alvira MR Lu Y Calcedo R Zhou X Wilson JM Clades of Adeno-associated viruses are widely disseminated in human tissues J Virol 2004 78 6381 8 10.1128/JVI.78.12.6381-6388.2004 15163731
Gao G, Vandenberghe LH, Alvira MR, Lu Y, Calcedo R, Zhou X, Wilson JM. Clades of Adeno-associated viruses are widely disseminated in human tissues. J Virol. 2004;78:6381–8.15163731 10.1128/JVI.78.12.6381-6388.2004
47. Wang JH Gessler DJ Zhan W Gallagher TL Gao G Adeno-associated virus as a delivery vector for gene therapy of human diseases Signal Transduct Target Ther 2024 9 78 10.1038/s41392-024-01780-w 38565561
Wang JH, Gessler DJ, Zhan W, Gallagher TL, Gao G. Adeno-associated virus as a delivery vector for gene therapy of human diseases. Signal Transduct Target Ther. 2024;9:78.38565561 10.1038/s41392-024-01780-w
48. Wang L Louboutin JP Bell P Greig JA Li Y Wu D Wilson JM Muscle-directed gene therapy for hemophilia B with more efficient and less immunogenic AAV vectors J Thromb Haemost 2011 9 2009 19 10.1111/j.1538-7836.2011.04491.x 21883883
Wang L, Louboutin JP, Bell P, Greig JA, Li Y, Wu D, Wilson JM. Muscle-directed gene therapy for hemophilia B with more efficient and less immunogenic AAV vectors. J Thromb Haemost. 2011;9:2009–19.21883883 10.1111/j.1538-7836.2011.04491.x
49. Hareendran S Balakrishnan B Sen D Kumar S Srivastava A Jayandharan GR Adeno-associated virus (AAV) vectors in gene therapy: immune challenges and strategies to circumvent them Rev Med Virol 2013 23 399 413 10.1002/rmv.1762 24023004
Hareendran S, Balakrishnan B, Sen D, Kumar S, Srivastava A, Jayandharan GR. Adeno-associated virus (AAV) vectors in gene therapy: immune challenges and strategies to circumvent them. Rev Med Virol. 2013;23:399–413.24023004 10.1002/rmv.1762
50. Varin J, Morival C, Maillard N, Adjali O, Cronin T. (2021) Risk mitigation of immunogenicity: a Key to Personalized Retinal Gene Therapy. Int J Mol Sci, 22.
51. Helfer-Hungerbuehler AK, Shah J, Meili T, Boenzli E, Li P, Hofmann-Lehmann R. (2021) Adeno-Associated Vector-Delivered CRISPR/SaCas9 System reduces Feline Leukemia Virus Production in Vitro. Viruses, 13.
52. Wei J Ran G Wang X Jiang N Liang J Lin X Ling C Zhao B Gene manipulation in liver ductal organoids by optimized recombinant adeno-associated virus vectors J Biol Chem 2019 294 14096 104 10.1074/jbc.RA119.008616 31366731
Wei J, Ran G, Wang X, Jiang N, Liang J, Lin X, Ling C, Zhao B. Gene manipulation in liver ductal organoids by optimized recombinant adeno-associated virus vectors. J Biol Chem. 2019;294:14096–104.31366731 10.1074/jbc.RA119.008616
53. Holehonnur R Luong JA Chaturvedi D Ho A Lella SK Hosek MP Ploski JE Adeno-associated viral serotypes produce differing titers and differentially transduce neurons within the rat basal and lateral amygdala BMC Neurosci 2014 15 28 10.1186/1471-2202-15-28 24533621
Holehonnur R, Luong JA, Chaturvedi D, Ho A, Lella SK, Hosek MP, Ploski JE. Adeno-associated viral serotypes produce differing titers and differentially transduce neurons within the rat basal and lateral amygdala. BMC Neurosci. 2014;15:28.24533621 10.1186/1471-2202-15-28
54. Jolle C Deglon N Pythoud C Bouzier-Sore AK Pellerin L Development of efficient AAV2/DJ-Based viral vectors to selectively Downregulate the expression of neuronal or astrocytic target proteins in the Rat Central Nervous System Front Mol Neurosci 2019 12 201 10.3389/fnmol.2019.00201 31481874
Jolle C, Deglon N, Pythoud C, Bouzier-Sore AK, Pellerin L. Development of efficient AAV2/DJ-Based viral vectors to selectively Downregulate the expression of neuronal or astrocytic target proteins in the Rat Central Nervous System. Front Mol Neurosci. 2019;12:201.31481874 10.3389/fnmol.2019.00201
55. Chen X Wolfe DA Bindu DS Zhang M Taskin N Goertsen D Shay TF Sullivan EE Huang SF Kumar R Functional gene delivery to and across brain vasculature of systemic AAVs with endothelial-specific tropism in rodents and broad tropism in primates Nat Commun 2023 14 3345 10.1038/s41467-023-38582-7 37291094
Chen X, Wolfe DA, Bindu DS, Zhang M, Taskin N, Goertsen D, Shay TF, Sullivan EE, Huang SF, Kumar R, S., et al. Functional gene delivery to and across brain vasculature of systemic AAVs with endothelial-specific tropism in rodents and broad tropism in primates. Nat Commun. 2023;14:3345.37291094 10.1038/s41467-023-38582-7
56. Hickey RD Lillegard JB Fisher JE McKenzie TJ Hofherr SE Finegold MJ Nyberg SL Grompe M Efficient production of Fah-null heterozygote pigs by chimeric adeno-associated virus-mediated gene knockout and somatic cell nuclear transfer Hepatology 2011 54 1351 9 10.1002/hep.24490 21674562
Hickey RD, Lillegard JB, Fisher JE, McKenzie TJ, Hofherr SE, Finegold MJ, Nyberg SL, Grompe M. Efficient production of Fah-null heterozygote pigs by chimeric adeno-associated virus-mediated gene knockout and somatic cell nuclear transfer. Hepatology. 2011;54:1351–9.21674562 10.1002/hep.24490
57. Chen X, Wolfe DA, Bindu DS, Zhang M, Taskin N, Goertsen D, Shay TF, Sullivan E, Huang SF, Kumar SR et al. (2023) Functional gene delivery to and across brain vasculature of systemic AAVs with endothelial-specific tropism in rodents and broad tropism in primates. bioRxiv.
58. Gong Y Berenson A Laheji F Gao G Wang D Ng C Volak A Kok R Kreouzis V Dijkstra IM Intrathecal Adeno-Associated viral vector-mediated gene delivery for Adrenomyeloneuropathy Hum Gene Ther 2019 30 544 55 10.1089/hum.2018.079 30358470
Gong Y, Berenson A, Laheji F, Gao G, Wang D, Ng C, Volak A, Kok R, Kreouzis V, Dijkstra IM, et al. Intrathecal Adeno-Associated viral vector-mediated gene delivery for Adrenomyeloneuropathy. Hum Gene Ther. 2019;30:544–55.30358470 10.1089/hum.2018.079
59. Ertl HCJ Immunogenicity and toxicity of AAV gene therapy Front Immunol 2022 13 975803 10.3389/fimmu.2022.975803 36032092
Ertl HCJ. Immunogenicity and toxicity of AAV gene therapy. Front Immunol. 2022;13:975803.36032092 10.3389/fimmu.2022.975803
60. Sadikot RT Blackwell TS Bioluminescence imaging Proc Am Thorac Soc 2005 2 537 40 10.1513/pats.200507-067DS 16352761
Sadikot RT, Blackwell TS. Bioluminescence imaging. Proc Am Thorac Soc. 2005;2:537–40.16352761 10.1513/pats.200507-067DS
61. Ezra-Elia R Obolensky A Ejzenberg A Ross M Mintz D Banin E Ofri R Can an in vivo imaging system be used to determine localization and biodistribution of AAV5-mediated gene expression following subretinal and intravitreal delivery in mice? Exp Eye Res 2018 176 227 34 10.1016/j.exer.2018.08.021 30171858
Ezra-Elia R, Obolensky A, Ejzenberg A, Ross M, Mintz D, Banin E, Ofri R. Can an in vivo imaging system be used to determine localization and biodistribution of AAV5-mediated gene expression following subretinal and intravitreal delivery in mice? Exp Eye Res. 2018;176:227–34.30171858 10.1016/j.exer.2018.08.021
62. Pacak CA Sakai Y Thattaliyath BD Mah CS Byrne BJ Tissue specific promoters improve specificity of AAV9 mediated transgene expression following intra-vascular gene delivery in neonatal mice Genet Vaccines Ther 2008 6 13 10.1186/1479-0556-6-13 18811960
Pacak CA, Sakai Y, Thattaliyath BD, Mah CS, Byrne BJ. Tissue specific promoters improve specificity of AAV9 mediated transgene expression following intra-vascular gene delivery in neonatal mice. Genet Vaccines Ther. 2008;6:13.18811960 10.1186/1479-0556-6-13
63. Chadman KK, Adayev T, Udayan A, Ahmed R, Dai CL, Goodman JH, Meeker H, Dolzhanskaya N, Velinov M. (2023) Efficient delivery of FMR1 across the blood brain barrier using AAVphp construct in adult FMR1 KO mice suggests the feasibility of Gene Therapy for Fragile X Syndrome. Genes (Basel), 14.
64. Zheng Y Xu X Fan R Jiang H Guo Q Han X Liu Y Luo G Intravitreal Delivery of rAAV2-hSyn-hRS1 results in retinal ganglion cell-specific gene expression and retinal improvement in the Rs1-KO mouse Hum Gene Ther 2024 35 342 54 10.1089/hum.2023.209 38661546
Zheng Y, Xu X, Fan R, Jiang H, Guo Q, Han X, Liu Y, Luo G. Intravitreal Delivery of rAAV2-hSyn-hRS1 results in retinal ganglion cell-specific gene expression and retinal improvement in the Rs1-KO mouse. Hum Gene Ther. 2024;35:342–54.38661546 10.1089/hum.2023.209
65. Bohlen MO McCown TJ Powell SK El-Nahal HG Daw T Basso MA Sommer MA Samulski RJ Adeno-Associated Virus Capsid-promoter interactions in the Brain Translate from Rat to the Nonhuman Primate Hum Gene Ther 2020 31 1155 68 10.1089/hum.2020.196 32940068
Bohlen MO, McCown TJ, Powell SK, El-Nahal HG, Daw T, Basso MA, Sommer MA, Samulski RJ. Adeno-Associated Virus Capsid-promoter interactions in the Brain Translate from Rat to the Nonhuman Primate. Hum Gene Ther. 2020;31:1155–68.32940068 10.1089/hum.2020.196
66. Powell SK Samulski RJ McCown TJ AAV capsid-promoter interactions determine CNS cell-selective gene expression in vivo Mol Ther 2020 28 1373 80 10.1016/j.ymthe.2020.03.007 32213322
Powell SK, Samulski RJ, McCown TJ. AAV capsid-promoter interactions determine CNS cell-selective gene expression in vivo. Mol Ther. 2020;28:1373–80.32213322 10.1016/j.ymthe.2020.03.007
67. Hordeaux J Wang Q Katz N Buza EL Bell P Wilson JM The Neurotropic properties of AAV-PHP.B are limited to C57BL/6J mice Mol Ther 2018 26 664 8 10.1016/j.ymthe.2018.01.018 29428298
Hordeaux J, Wang Q, Katz N, Buza EL, Bell P, Wilson JM. The Neurotropic properties of AAV-PHP.B are limited to C57BL/6J mice. Mol Ther. 2018;26:664–8.29428298 10.1016/j.ymthe.2018.01.018
68. Perleberg C, Kind A, Schnieke A. (2018) Genetically engineered pigs as models for human disease. Dis Model Mech, 11.
69. Liu Y Beyer A Aebersold R On the Dependency of Cellular protein levels on mRNA abundance Cell 2016 165 535 50 10.1016/j.cell.2016.03.014 27104977
Liu Y, Beyer A, Aebersold R. On the Dependency of Cellular protein levels on mRNA abundance. Cell. 2016;165:535–50.27104977 10.1016/j.cell.2016.03.014
